Lv31
395 积分 2020-08-03 加入
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
1小时前
待确认
The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the Tenth Edition TNM Classification
1小时前
已完结
Lung Cancer
5天前
已完结
EGFR Antagonists in Cancer Treatment
9天前
已完结
Review Article Molecular Origins of Cancer Share on Lung Cancer
9天前
已完结
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
12天前
已完结
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
12天前
已完结
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in C
12天前
已关闭
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
12天前
已完结
Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
14天前
已完结
皖公网安备34019202002308
